Pillstats
Rx only · Injection, Solution · Intramuscular

Methotrexate

Methotrexate Sodium

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US12 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)6851
US makers3 labelers
Packages17
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.966$1.93$2.90$3.86Dec 2025Apr 2026Jul 2026
$3.247
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
3
Active US suppliers
76%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

6.5K13K19K26K2025 Q12025 Q22025 Q32025 Q42026 Q1
20K
Rx · 2026 Q1
81K
Units dispensed
-12%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Eugia US LLCunknown7SUPPLYING
Hospira, Inc.unknown6SUPPLYING
Alembic Pharmaceuticals Limitedunknown4SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 13, 2023
    SHORTAGEDrug shortage: Methotrexate Sodium Injection (Hospira, Inc., a Pfizer Company)

    Methotrexate Sodium Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Oncology, Rheumatology.

  • Mar 15, 2021
    RECALLRecall (Class II): Methotrexate Injection, USP 50 mg/2mL (25 mg/mL) 5 x 2mL Single-Dose Vials, Sterile, Rx Only, Distributed by Hospira, I…

    CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC

  • Jun 27, 2012
    RECALLRecall (Class II): Methotrexate Injection, USP, 25 mg/mL, 40 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured fo…

    The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution. — Recalling firm: Hospira Inc. — Nationwide, including Puerto Rico and Guam. Product was also distributed internationally to Australia, Belgium, Cana…